Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

348

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

January 31, 2027

Conditions

Type 2 Diabetic Nephropathy

Interventions

DRUG

DWP16001 Placebo

1 tablet, Orally, Once daily single dose

DRUG

DWP16001 0.3mg

1 tablet, Orally, Once daily single dose

Trial Locations (1)

Korea university ansan hospital, Ansan